Improvement of treatment adherence after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany

Abstract

<b>Background:</b> Randomized controlled trials showed significant clinical benefits of extrafine single-inhaler triple therapy (efSITT) consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium in the treatment of asthmatics not adequately controlled with ICS/LABA, and with ≥1 exacerbation in the last year. <b>Aims and objectives:</b> The TriMaximize study aims to provide a real-world view of the characteristics and therapy pathways of patients with moderate-severe asthma prescribed efSITT in real-world practice and to characterize the effects of efSITT on health-related outcomes. Here, we present interim data on the changes in treatment adherence in the first 189 patients from Germany after 3 months of treatment with efSITT. <b>Methods:</b> This is a multicenter multicountry prospective non-interventional study following asthmatics prescribed efSITT for 1-3 years. Treatment adherence is assessed by the Test of Adherence to Inhalers. <b>Results:</b> The majority (73.7%) were on prior ICS/LABA treatment, and 23.2% on prior ICS/LABA/LAMA. At baseline the proportion of patients with a poor, medium or good adherence score (AS) was 28%, 27.5% and 44.4%, respectively. After 3 months of treatment with efSITT the proportion of patients with a poor AS decreased to 18.5%, while that of patients with a medium or good AS increased to 30.2% and 51.3%, respectively. 50.5% of patients with a poor or medium AS at baseline improved to a higher adherence category. <b>Conclusions:</b> TriMaximize is the first real-world study to show an improvement of treatment adherence in patients with moderate-severe asthma after switch from ICS/LABA or ICS/LABA/LAMA to efSITT.